Amgen, Inc. (NASDAQ:AMGN)

fda_logo

Is a Biosimilar (Generic) Top Cancer Drug for You?

There has been a movement to get generic pharmaceutical drugs to market with for years. The notion of "biosimilars" has grown as well. Effectively this is making biotech drugs into ...
Read Full Story »
biotech

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The short interest data are out for the November 28 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
DNA

Mixed Readings For Biotech Short Interest

The short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
145922793

Amgen Surprise, Discontinues Stomach Cancer Drug Study

Amgen Inc. (NASDAQ: AMGN) announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer. This includes phase 3 RILOMET-1 and RILOMET-2 studies. The decision to discontinue ...
Read Full Story »
Biotechnology word cloud

Biotech Short Interest Becomes Stock Specific (Updated)

The short interest data are out for the October 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
health care

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Many investors want to try to find the stocks that are going to offer the traditional “beat and raise estimates” before they release quarterly earnings reports. Actually, it has always ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Alibaba, Amgen, Cliffs, Michael Kors, Sanofi, Yahoo! and More

Stocks are looking for direction on Wednesday with mixed indexes, but that is after another massive rally on Tuesday that took the DJIA back over 17,000 again. Earnings season is ...
Read Full Story »
Pills

Amgen Posts 52-Week High, Beats It Again After Earnings

Drug maker Amgen Inc. (NASDAQ: AMGN) reported third-quarter 2014 results after markets closed Monday afternoon. The biotech company reported quarterly adjusted diluted earnings per share (EPS) of $2.30 and revenues ...
Read Full Story »
Biotechnology word cloud

Biotech Short Interest Becomes Stock Specific

The short interest data are out for the October 15, settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Stock Split Image

The Plan to Drive Amgen Shares Up Over 70%

Amgen Inc. (NASDAQ: AMGN) used to be the king of biotech by size. That was then, and now is the time for a break-up or other efforts. At least that ...
Read Full Story »
Biotechnology word cloud

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

The recent market sell-off spared no sector, and the top biotechnology stocks were treated with their own trip to the woodshed. Rising trends in prescriptions and higher, yet beatable increases ...
Read Full Story »
Biotechnology word cloud

Short Interest in Biotech Becomes Company Specific

The short interest data are out for the end of September settlement date. Biotech companies are considered a riskier group of stocks with big upside and big downside. FDA rulings ...
Read Full Story »
biotech

3 Likely Biotech Buyout Candidates

The pharmaceutical business is a difficult one, because patent expiration and competition are always omnipresent factors. Obviously major companies like to keep large research and development projects moving at full ...
Read Full Story »
research

Short Sellers Make Moves in Key Biotech Stocks

The short interest report is out for the September 15 settlement date, and here 247 Wall St. has decided to focus on the biotech sector. Short sellers are often active ...
Read Full Story »
495784183

10 Companies Cutting the Most Jobs

Through August, planned job cuts were slightly lower than they were during the first eight months of 2013. In all, companies have announced just under 333,000 planned layoffs so far ...
Read Full Story »